Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study

Related articles

1. Prevention of incident SARS-CoV-2 infection through combined intranasal and intradermal administration of the GLS-5310 DNA vaccine during the Omicron outbreak

   This article has 13 authors:

   1. Joel Maslow
   2. Javier Morales-Ramirez
   3. Christine Roberts
   4. Susan Spruill
   5. Deborah Kane
   6. Melissa Gulley
   7. Joel Muñoz-Coreano
   8. Sonia Velazquez-Navarro
   9. Jay Meyer
   10. Sagar Kudchodkar
   11. Susan Mikota
   12. Stephen Kania
   13. Young Park

2. Impact of first SARS-CoV-2 infection variant on serological responses against Omicron: findings from the SIREN study

   This article has 13 authors:

   1. Ferdinando Insalata
   2. Ana Atti
   3. Edward J. Carr
   4. Ashley D. Otter
   5. SIREN study group
   6. Sarah Foulkes
   7. Giulia Dowgier
   8. Agnieszka Hobbs
   9. Mary Y. Wu
   10. Susan Hopkins
   11. Andre Charlett
   12. Rupert Beale
   13. Victoria Hall

3. Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants

   This article has 13 authors:

   1. Amparo L. Figueroa
   2. Bethany Girard
   3. Darin K Edwards
   4. Arshan Nasir
   5. Kimball Johnson
   6. Steven Hack
   7. Xin Cao
   8. Elizabeth de Windt
   9. Veronica Urdaneta
   10. Frances Priddy
   11. Rituparna Das
   12. David C Montefiori
   13. Spyros Chalkias